TY - JOUR
T1 - On-site HIV testing in residential drug treatment units
T2 - Results of a nationwide survey
AU - Strauss, Shiela M.
AU - Des Jarlais, Don C.
AU - Astone, Janetta
AU - Vassilev, Zdravko P.
N1 - Funding Information:
The authors thank Deborah Trunzo of the Office of Applied Studies, Substance Abuse and Mental Health Services Administration, for her kind assistance in arranging for the project's use of the I-SATS database. They also thank Sarah Krassenbaum, Kim Sanders, and Kristine Ziek, the project interviewers, for their consistent efforts to ensure the best possible rate of treatment program participation in the research, and whose high standards are reflected in the excellent quality of the data. This study was supported by a grant (DA13409) from the National Institute on Drug Abuse, National Institutes of Health.
PY - 2003
Y1 - 2003
N2 - Objective. Residential drug treatment units are uniquely situated to provide HIV testing and counseling to their patients. This article examines the extent to which residential drug treatment units in the United States provide HIV testing on-site, and identifies organizational and institutional characteristics that differentiate units in which on-site HIV testing is available from those in which it is not. Methods. The analyses use data collected in telephone interviews with unit managers from a random nationwide sample (N=138) of residential drug treatment units in 2001. Results. About half (48.6%) of the residential drug treatment units made HIV testing available to their patients on-site. Residential units were significantly more likely to make on-site testing available if they were larger (i.e., had a greater number of patients treated each month or had a greater number of staff that provided direct patient services) and if they were publicly rather than privately owned. Provision of on-site HIV testing was significantly correlated with having a medical orientation, i.e., with being operated by a hospital, with the unit viewing itself as patients' primary medical provider, or with providing medical care to the patients either on-site or at another part of the same treatment agency. Conclusion. In view of the critical importance of HIV testing for individuals who use illicit drugs and the existence of a simplified testing protocol involving saliva samples (eliminating the need for phlebotomy), units that do not have a medical orientation should be encouraged to make HIV testing available on-site.
AB - Objective. Residential drug treatment units are uniquely situated to provide HIV testing and counseling to their patients. This article examines the extent to which residential drug treatment units in the United States provide HIV testing on-site, and identifies organizational and institutional characteristics that differentiate units in which on-site HIV testing is available from those in which it is not. Methods. The analyses use data collected in telephone interviews with unit managers from a random nationwide sample (N=138) of residential drug treatment units in 2001. Results. About half (48.6%) of the residential drug treatment units made HIV testing available to their patients on-site. Residential units were significantly more likely to make on-site testing available if they were larger (i.e., had a greater number of patients treated each month or had a greater number of staff that provided direct patient services) and if they were publicly rather than privately owned. Provision of on-site HIV testing was significantly correlated with having a medical orientation, i.e., with being operated by a hospital, with the unit viewing itself as patients' primary medical provider, or with providing medical care to the patients either on-site or at another part of the same treatment agency. Conclusion. In view of the critical importance of HIV testing for individuals who use illicit drugs and the existence of a simplified testing protocol involving saliva samples (eliminating the need for phlebotomy), units that do not have a medical orientation should be encouraged to make HIV testing available on-site.
UR - http://www.scopus.com/inward/record.url?scp=0037288133&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037288133&partnerID=8YFLogxK
U2 - 10.1016/S0033-3549(04)50215-7
DO - 10.1016/S0033-3549(04)50215-7
M3 - Article
C2 - 12604763
AN - SCOPUS:0037288133
SN - 0033-3549
VL - 118
SP - 37
EP - 43
JO - Public Health Reports
JF - Public Health Reports
IS - 1
ER -